Últimas noticias sobre AstraZeneca (NASDAQ:AZN) Bolsa

AstraZeneca

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.

Novo Nordisk

Equities

FTXH

iShares Dow Jones US Pharmaceuticals Index Fund

KURE

PILL

Merrill Lynch Pharmaceutical HOLDRs Trust

RHHBY

Los aranceles de Trump podrían afectar a Novo Nordisk y otros gigantes farmacéuticos. Barclays advierte de impacto en márgenes y suministro.

Novo Nordisk, en la mira por los posibles aranceles farmacéuticos de Trump

News

Markets

AMGN

Amgen lanza ensayos de fase 3 para MariTide, su inyección contra la obesidad. ¿Podrá competir con Ozempic y Wegovy? Descubre su potencial.

Amgen (AMGN) desafía a Novo Nordisk y Eli Lilly con MariTide: ¿Una nueva era para la obesidad?

$BTC

$ETH

FLUIF

IDEXY

LABFF

El Ibex 35 y las bolsas europeas cotizan estables este martes. El Ibex sube un 0,07% a 11.280 puntos, tras las alzas del lunes en Europa y Wall Street.

Ibex 35 sube ligeramente mientras los mercados europeos se estabilizan este martes

WIIM

AstraZeneca shares are trading higher after the company reported better-than-expected Q2 sales results. Also, the CFO said the company will not be significantly impacted by the US tariffs.

Biotech

Global

General

During Conf Call, AstraZeneca CFO Reportedly Says Co Will Not Be Significantly Impacted By U.S. Tariffs; If Any Impact, It Is Going To Be "Very Short Lived"

AstraZeneca Plc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) on Tuesday reported second-quarter 2025 sales of $14.46 billion, up 12% year over year (+11% at constant currency), marginally beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $14.07 billion</a>, driven by double-digit growth in oncology and biopharmaceuticals.
The company's adjusted EPADS&nbsp;reached&nbsp;$1.08, missing the consensus of $1.10. The adjusted EPS was $2.17 (1 ADR = 2 Common Shares).
Also Read: <a href="https://www.benzinga.com/news/health-care/25/07/46555155/trump-tariffs-forces-astrazeneca-to-bring-substantial-pharmaceutical-production-to-us" target="_blank" rel="noreferrer noopener">Trump Tariffs Force AstraZeneca To Bring Substantial Pharmaceutical Production To US</a>
AstraZeneca's top business, oncology (cancer), accounted for 44% of total sales. It <a href="https://www.astrazeneca.com/content/dam/az/PDF/2025/h1q2/H1-and-Q2-2025-results-announcement.pdf" target="_blank" rel="noreferrer noopener">increased</a> 18% (up 18% on constant currency) to $6.31 billion.
<ul class="wp-block-list">
<li>Tagrisso sales were up 13% to $1.81 billion (12% at CER), Imfinzi revenues were up 27% (+26%) to $1.46 billion, Calquence sales increased 10% to $872 million, Lynparza sales increased 13% (+11%) to $838 million, and Enhertu revenue was up 41% (42% at CER) to $666 million.</li>
<li>On Monday, the Food and Drug Administration (FDA)&nbsp;<a href="https://www.astrazeneca.com/media-centre/press-releases/2025/imfinzi-granted-priority-review-and-breakthrough-therapy-designation-us-patients-with-resectable-early-stage-gastric-gastroesophageal-junction-cancers.html" target="_blank" rel="noreferrer noopener">accepted</a> and granted Priority Review in the U.S. for AstraZeneca's supplemental Biologics License Application for Imfinzi (durvalumab) for resectable, early-stage and locally advanced gastric and gastroesophageal junction cancers.</li>
<li>The Prescription Drug User Fee Act date, the FDA action date for their regulatory decision, is anticipated during the fourth quarter of 2025.</li>
</ul>
Cardiovascular, renal, and metabolism (CVRM) sales accounted for 23%, which increased by 3% (up 3% at CER) to&nbsp;$3.64 billion.
<ul class="wp-block-list">
<li>The largest selling drug in the segment, Farxiga, accounted for 15% of sales. </li>
<li>It was up 11% (10% at CER) to $2.15 billion.</li>
</ul>
Respiratory &amp; Immunology (R&amp;I) sales increased 13% (12% CER) to $2.15 billion.
<ul class="wp-block-list">
<li>Symbicort revenues fell 1% (-1% CER) to $715 million, and Fasenra sales increased 19% (+18%) to $502 million.</li>
</ul>
Rare Disease drug sales increased by 7% to&nbsp;$2.94 billion.
<ul class="wp-block-list">
<li>Ultomiris sales were up 25% (23% at CER) to $1.18 billion, offset by a 24% decline in Soliris (-22% at CER) to $530 million.</li>
</ul>
China's sales accounted for 12% of quarterly sales, up 5% on a reported basis to&nbsp;$1.71 billion (+5% at CER).
Pascal Soriot, CEO of AstraZeneca, <a target="_blank" href="https://www.astrazeneca.com/media-centre/press-releases/2025/h1-and-q2-2025.html" rel="noreferrer noopener">commented</a> on Tuesday, "Our strong momentum in revenue growth continued through the first half of the year, and the delivery from our broad and diverse pipeline has been excellent, with 12 positive key Phase III trial readouts, including for&nbsp;baxdrostat,&nbsp;gefurulimab, and&nbsp;Tagrisso, in just the past few weeks.&#8221;
Guidance:&nbsp;For fiscal year 2025, AstraZeneca <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/45069668/astrazeneca-q1-sales-and-earnings-rise-warns-china-import-tax-could-be-up-to-8-million-ceo-says-tariff-related-exposure-limited" rel="noreferrer noopener">reaffirms total revenue</a> to increase by a high single-digit percentage and core EPS to increase by a low double-digit percentage.
Pipeline Update: AstraZeneca removed three phase 1 underdevelopment assets from its pipeline, including:
<ul class="wp-block-list">
<li>AZD5851 GPC3 CAR-T hepatocellular carcinoma</li>
<li>AZD6422 CLDN18.2 CAR-T solid tumors.</li>
<li>NT-125 autologous, fully-individualised, multi-specific TCR-T targeting neoantigens in solid tumors.</li>
</ul>
The company also <a target="_blank" href="https://www.astrazeneca.com/content/dam/az/PDF/2025/h1q2/H1-and-Q2-2025-results-clinical-trials-appendix.pdf" rel="noreferrer noopener">removed</a> an additional indication for zibotentan/dapagliflozin, an endothelin A receptor antagonist/SGLT2 inhibitor, for liver cirrhosis.
Price Action: AZN stock is up 2.60% at $73.70&nbsp;during the premarket session at the last check on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46678476/sony-files-federal-lawsuit-against-tencent-claims-upcoming-game-light-of-motiram-rips-off-horizons-story-gameplay-and-art" target="_blank" rel="noreferrer noopener">Sony Files Federal Lawsuit Against Tencent, Claims Upcoming Game &#8216;Light Of Motiram&#8217; Rips Off Horizon&#8217;s Story, Gameplay And Art</a></li>
</ul>
Image: Shutterstock

Earnings

Large Cap

Guidance

Health Care

Movers

Trading Ideas

AstraZeneca Q2 Sales Beat Estimates On Strong Cancer Drugs Revenues, Reaffirms 2025 Outlook

ACGL

ALKS

APAM

ARCC

ASTL

ATRC

AUDC

BAFN

BAND

BBNX

BKNG

BRSL

BRSP

CAKE

CARR

CBRE

CECO

CHCT

CMPR

CNOB

CSTM

CVEO

CVLT

DHIL

ENIC

EXLS

FCPT

FELE

FIBK

FRSH

FTAI

FYBR

GATX

HOUS

HUBB

ILPT

INCY

JBGS

JBLU

KNSA

LOGI

LSTR

LXFR

MARA

MDLZ

NEOG

NMIH

NWBI

Earnings Scheduled For July 29, 2025

Guidance AstraZeneca reiterates its Total Revenue and Core EPS guidance for FY 2025 at CER, based on the average foreign exchange rates through 2024. &nbsp;
Total Revenue is expected to increase by a high single-digit percentage
Core EPS is expected to increase by a low double-digit percentage &nbsp;
The Core Tax rate is expected to be between 18-22%&nbsp;

AstraZeneca Reaffirms 2025 Guidance: Expects High Single-Digit Revenue Growth, Low Double-Digit Core EPS Growth, And 18–22% Core Tax Rate

AstraZeneca (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) reported quarterly earnings of $1.08 per share which missed the analyst consensus estimate of $1.10 by 1.36 percent. This is a 9.6 percent increase over earnings of $0.99 per share from the same period last year. The company reported quarterly sales of $14.46 billion which beat the analyst consensus estimate of $14.07 billion by 2.75 percent. This is a 11.35 percent increase over sales of $12.98 billion the same period last year.

Earnings Beats

Earnings Misses

AstraZeneca Q2 Adj. EPS $1.08 Misses $1.10 Estimate, Sales $14.46B Beat $14.07B Estimate

Biotechnology firms are increasingly turning to innovative combination therapies to <a href="https://www.benzinga.com/general/biotech">tackle hard-to-treat cancers</a>, with promising results sparking investor interest. AIM ImmunoTech Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIM#NYSE">AIM</a>) is the latest to capture attention, as its stock soars following a promising mid-year update from the DURIPANC Phase 2 study.
The study is evaluating Ampligen (rintatolimod) in combination with AstraZeneca Plc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) anti-PD-L1 immune checkpoint inhibitor, Imfinzi (durvalumab), in metastatic pancreatic cancer patients with <a href="https://www.benzinga.com/general/biotech" target="_blank" rel="noopener">stable disease following FOLFIRINOX treatment</a>.
The DURIPANC study, a collaboration with AstraZeneca and Erasmus Medical Center in the Netherlands, is an investigator-initiated, exploratory, open-label, single-center study expected to enroll up to 25 subjects in the Phase 2 portion.
As of the mid-year report, 14 subjects had been enrolled in DURIPANC. The primary objective of the study is to determine the clinical benefit rate of the combination therapy; the secondary/exploratory objectives include assessing overall survival (OS), progression-free survival (PFS), and initiating immune monitoring using available tissue biopsies <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/g46657801/aim-immunotech-reports-positive-mid-year-safety-and-efficacy-data-from-phase-2-study-evaluating-am" rel="noreferrer noopener">and peripheral immune profiling</a>.
Following FOLFIRINOX, maintenance or second-line immunotherapies have historically shown limited survival benefit in comparison trials. Compared to these data, the DURIPANC study mid-year report shows continuing promising early signs of both no significant toxicity and superior PFS and OS:
<ul class="wp-block-list">
<li>No significant toxicity, an encouraging safety profile for a post-chemo setting.</li>
<li>Around 21% of patients have progression-free survival (PFS) of over 6 months (3/14), with an additional 21% not yet progressed.</li>
<li>The majority (64%) of eligible patients had an overall survival of over 6 months, which is better than expected in this setting.</li>
</ul>
AIM has developed an intellectual property plan specific to pancreatic cancer that includes a recently issued U.S. patent for Ampligen as an oncology treatment in combination with an anti-PD-L1, extending protection to Aug. 9, 2039.
AIM Price Action: AIM ImmunoTech shares were up 36.79% at $11.49 at the time of publication on Monday<a href="https://www.benzinga.com/pro/" target="_blank" rel="noreferrer noopener">, according to Benzinga Pro data.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46657284/palantirs-next-stop-is-200-says-jim-cramer-as-pltr-glides-like-a-knife-through-butter" target="_blank" rel="noreferrer noopener">Palantir&#8217;s Next Stop Is $200, Says Jim Cramer As PLTR Glides &#8216;Like A Knife Through Butter&#8217;</a></li>
</ul>
Photo: jittawit21/Shutterstock

Why Is Micro-Cap AIM ImmunoTech Stock Surging?

AstraZeneca (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) is gearing up to announce its quarterly earnings on Tuesday, 2025-07-29. Here's a quick overview of what investors should know before the release.
Analysts are estimating that AstraZeneca will report an earnings per share (EPS) of $1.10.
AstraZeneca bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
Last quarter the company beat EPS by $0.14, which was followed by a 0.11% increase in the share price the next day.
Here's a look at AstraZeneca's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.110</td>
<td>1.070</td>
<td>1.03</td>
<td>1.20</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.245</td>
<td>1.045</td>
<td>1.04</td>
<td>0.99</td>
</tr>
<tr>
<td>Price Change %</td>
<td>0.0%</td>
<td>-1.0%</td>
<td>0.0%</td>
<td>-0.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1753711356_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of AstraZeneca were trading at $72.66 as of July 25. Over the last 52-week period, shares are down 7.46%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/AZN/earnings">To track all earnings releases for AstraZeneca visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AstraZeneca Earnings Preview

<ul>
<li>Based on MATTERHORN Phase III trial results which demonstrated a statistically significant and clinically meaningful event-free survival benefit&nbsp;</li>
<li>If approved, this will be the first and only perioperative immunotherapy-based regimen in this setting</li>
</ul>

The FDA Has Accepted And Granted Priority Review To AstraZeneca's Supplemental Biologics License Application For Imfinzi (Durvalumab) For Resectable, Early-stage And Locally Advanced Gastric And Gastroesophageal Junction Cancers

AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) on Thursday reported high-level results from the PREVAIL Phase 3 trial evaluating the safety and efficacy of gefurulimab in adults with generalized myasthenia gravis (gMG). The trial <a target="_blank" href="https://www.benzinga.com/quote/AZN" rel="noreferrer noopener">enrolled 260 patients</a>.
MG is a chronic autoimmune disorder that causes muscle weakness and fatigue. The disease is characterized by antibodies against the acetylcholine receptor, a protein found on the surface of nerve cells that plays a key role in muscle contraction.
In adults with anti-acetylcholine receptor (AChR) antibody-positive (Ab+) generalized myasthenia gravis, gefurulimab <a href="https://www.astrazeneca.com/media-centre/press-releases/2025/gefurulimab-nanobody-met-phase-iii-endpoints.html" target="_blank" rel="noreferrer noopener">met</a> its primary and all secondary endpoints.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44698541/johnson-johnsons-new-compelling-data-shows-sustained-symptom-improvement-in-muscular-disease-patients" rel="noreferrer noopener">Johnson &amp; Johnson&#8217;s New &#8216;Compelling Data&#8217; Shows Sustained Symptom Improvement In Muscular Disease Patients</a>
Data demonstrated a statistically significant and clinically meaningful improvement from baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) total score at week 26 compared to placebo.
gMG is a rare, debilitating, chronic, autoimmune neuromuscular disease that leads to a loss of muscle function and severe weakness.
Gefurulimab was well-tolerated, and the safety profile was consistent with previous trials of C5 inhibitors in gMG with no new safety signals observed. These data will be presented at a forthcoming medical meeting and shared with global regulatory authorities.
In April, Cartesian Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAC#NASDAQ">RNAC</a>) revealed 12-month efficacy and safety data from the Phase 2b trial of Descartes-08, the lead cell therapy candidate, in participants with <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44698463/cartesian-therapeutics-reports-strong-12-month-data-for-lead-cell-therapy-in-myasthenia-gravis-patients" rel="noreferrer noopener">generalized myasthenia gravis</a>.
In March, Amgen&nbsp;Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) announced new data from the Phase 3 MINT trial of Uplizna&nbsp;(inebilizumab-cdon) for adult patients with <a target="_blank" href="https://www.benzinga.com/25/03/44307450/amgens-uplizna-shows-improved-symptoms-in-patients-with-muscle-weakness-disorder-over-one-year" rel="noreferrer noopener">generalized myasthenia gravis</a>.
The results demonstrated the durable and sustained efficacy of Uplizna in patients with acetylcholine receptor autoantibody-positive (AChR+) gMG with two doses a year following an <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44301271/uplizna-inebilizumab-cdon-significantly-improves-generalized-myasthenia-gravis-symptoms-in-acetylc" rel="noreferrer noopener">initial loading dose</a>.
The trial demonstrated continued improvement in the efficacy of Uplizna compared to placebo as measured by the change in baseline of Myasthenia Gravis Activities of Daily Living (MG-ADL) score in the AChR+ subpopulation through week 52.
Price Action: AZN stock is up 1.45% at $$74.06 at the last check on Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/fda/25/06/46175777/fda-flags-major-safety-concerns-for-argenxs-nerve-disorder-drug-stock-falls" target="_blank" rel="noreferrer noopener">FDA Flags Major Safety Concerns For Argenx&#8217;s Nerve Disorder Drug, Stock Falls</a></li>
</ul>
Photo by JHVEPhoto via Shutterstock

RNAC

AstraZeneca Prepares Showdown With JNJ, Amgen With Phase 3 Win For Myasthenia Gravis Drug Candidate

Once-weekly self-administered subcutaneous C5 inhibitor showed statistically significant and clinically meaningful reduction in disease severity at week 26

AstraZeneca's Topline Data From Phase 3 Trial For Anti-acetylcholine Receptor Antibody-positive Generalized Myasthenia Gravis Showed That Gefurulimab Met Its Primary And All Secondary Endpoints

<a href="https://www.cnbc.com/2025/07/23/healthy-returns-researchers-move-closer-to-a-universal-cancer-vaccine.html" title="https://www.cnbc.com/2025/07/23/healthy-returns-researchers-move-closer-to-a-universal-cancer-vaccine.html">https://www.cnbc.com/2025/07/23/healthy-returns-researchers-move-closer-to-a-universal-cancer-vaccine.html</a>

BNTX

MRNA

NVAX

'Researchers Move Closer To A Universal Cancer Vaccine' - CNBC

AstraZeneca's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NYSE">AZN</a>) short percent of float has fallen 8.33% since its last report. The company recently reported that it has 6.81 million shares sold short, which is 0.22% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.76 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>AstraZeneca Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1753286427_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for AstraZeneca has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing AstraZeneca's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, AstraZeneca's peer group average for short interest as a percentage of float is 3.48%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

What's Driving the Market Sentiment Around AstraZeneca?

AstraZeneca plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) announced on Tuesday that it will invest $50 billion in the <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">United States by 2030</a>.
The investment will create new, highly skilled direct and indirect jobs nationwide, the company <a target="_blank" href="https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-plans-to-invest-50bn-dollars-in-the-us.html" rel="noreferrer noopener">said</a>.
The cornerstone of this landmark investment is a new multi-billion-dollar U.S. manufacturing facility that will produce drug substances for the company's weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9, and combination small-molecule products.
The new centre will produce small molecules, peptides, and oligonucleotides.
This multi-billion dollar capital investment is in addition to the $3.5 billion announced in November 2024.
The drug substance facility, planned for the Commonwealth of Virginia, would be AstraZeneca's largest single manufacturing investment in the world. It will leverage AI, automation, and data analytics to optimize production.
<h2 class="wp-block-heading">What Does The Investment Include?</h2>
The $50 billion investment across R&amp;D and manufacturing footprint in the U.S. over the next five years also includes:
<ul class="wp-block-list">
<li>Expansion of R&amp;D facility in Gaithersburg, Maryland</li>
<li>R&amp;D centre in Kendall Square, Cambridge, Massachusetts</li>
<li>Manufacturing facilities for cell therapy in Rockville, Maryland and Tarzana, California</li>
<li>Manufacturing expansion in Mount Vernon, Indiana</li>
<li>Specialty manufacturing expansion in Coppell, Texas</li>
<li>New sites to supply clinical trials.</li>
</ul>
The company said collectively, these investments will help deliver AstraZeneca's <a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38936595/astrazeneca-targets-ambitious-80b-in-total-revenue-by-2030-through-pipeline-expansion" rel="noreferrer noopener">ambition of reaching $80 billion</a> in Total Revenue by 2030, of which 50% would be generated in the U.S.
Howard Lutnick, U.S. Secretary of Commerce, said: "For decades Americans have been reliant on foreign supply of key pharmaceutical products. President Trump and our nation's new tariff policies are focused on ending this structural weakness. We are proud that AstraZeneca has made the decision to bring substantial pharmaceutical production to our shores."
<a target="_blank" href="https://www.benzinga.com/25/05/45234032/fda-expands-surprise-inspections-at-foreign-drug-and-food-facilities-targets-double-standards-in-overseas-manufacturing-oversight" rel="noreferrer noopener">Amid tariff uncertainty</a>, many drug companies are investing to boost production within the U.S. Most recently, Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) said that it plans to invest an additional $2 billion in its existing manufacturing footprint in North Carolina's Research&nbsp;<a target="_blank" href="https://www.benzinga.com/news/health-care/25/07/46529101/biogen-bets-big-on-2-billion-expansion-to-boost-us-drug-manufacturing" rel="noreferrer noopener">Triangle Park (RTP)</a>.
Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) doubled&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43982604/eli-lilly-doubles-capital-spending-on-us-drug-manufacturing-with-50-billion-target" rel="noreferrer noopener">domestic medicine production</a>.
Thermo Fisher Scientific Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) announced it would invest an additional $2 billion in the U.S. over&nbsp;<a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44995428/thermo-fisher-doubles-down-on-us-manufacturing-in-2b-expansion-plan" rel="noreferrer noopener">the next four years</a>.
Medtech firm&nbsp;Becton, Dickinson, and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) also announced its intention to invest&nbsp;$2.5 billion&nbsp;in U.S. manufacturing capacity&nbsp;<a target="_blank" href="https://www.benzinga.com/general/health-care/25/05/45140102/potential-tariff-bites-into-becton-dickinson-2025-profit-outlook-company-will-invest-2-5-billion-to-boost-us-manufacturing" rel="noreferrer noopener">over the next five years</a>.
Regeneron Pharmaceuticals, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) seeks to nearly double its manufacturing capacity through a new agreement with&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44931246/regeneron-partners-with-japan-based-fujifilm-to-bolster-us-manufacturing-capacity-via-3-billion-deal" rel="noreferrer noopener">FUJIFILM Diosynth Biotechnologies</a>. Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) unveiled a $23 billion investment plan to expand in the U.S.&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44761201/novartis-commits-23-billion-to-expand-us-manufacturing-over-five-years-despite-tariffs-uncertaint" rel="noreferrer noopener">over the next five years</a>.
Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) plans to invest more than&nbsp;<a target="_blank" href="https://www.benzinga.com/markets/equities/25/03/44433978/johnson-johnson-to-invest-55-billion-in-us-to-boost-manufacturing-drug-discovery" rel="noreferrer noopener">$55 billion in the U.S. over the next four years</a>. Roche Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) announced that it will invest $50 billion in the U.S. over&nbsp;<a target="_blank" href="https://www.benzinga.com/topic/pharmaceuticals" rel="noreferrer noopener">the next five years.</a>
Bristol-Myers Squibb &amp; Co.'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Christopher Boerner, chair and chief executive officer,&nbsp;<a target="_blank" href="https://www.statnews.com/2025/05/05/bristol-myers-squibb-pharmaceutical-policy-us-trump-administration-innovation-tariffs/?tblci=GiCUX7wvU_AgmIIiQduNYr6JQuJQLy6SZJGvpyeZuCzyqiCN1VcoxvTN4f7-y-PqATDviEo" rel="noreferrer noopener">shared</a> plans to invest $40 billion in U.S. R&amp;D, technology, and manufacturing over the next five years. Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) announced it will invest at least&nbsp;$20 billion&nbsp;in&nbsp;the&nbsp;<a target="_blank" href="https://www.benzinga.com/25/05/45419235/sanofi-joins-other-big-pharma-to-navigate-potential-tariff-impact-with-at-least-20-billion-in-investments-through-2030" rel="noreferrer noopener">U.S.&nbsp;through 2030</a>. The bulk of the spending will go to R&amp;D and U.S. manufacturing.
Price Action: AZN stock is up 2.34% at $70.33 at the last check on Tuesday
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/07/46551856/pony-ai-stock-surges-as-autonomous-system-hits-key-milestone" target="_blank" rel="noreferrer noopener">Pony AI Stock Surges As Autonomous System Hits Key Milestone</a></li>
</ul>
Photo by JHVEPhoto via Shutterstock

BIIB

REGN

Trump Tariffs Forces AstraZeneca To Bring Substantial Pharmaceutical Production To US

Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) on Tuesday agreed to acquire Vicebio Ltd, a privately held biotechnology company headquartered in London, U.K.
The acquisition brings an early-stage combination vaccine candidate for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">both respiratory viruses</a>, and expands the capabilities in vaccine design and development with Vicebio&#8217;s &#8216;Molecular Clamp&#8217; technology.
The vaccine candidate complements Sanofi&#8217;s position in the respiratory vaccines space, where the company is present in flu and RSV prevention. It allows Sanofi to offer increased physician and patient choice in RSV and hMPV by adding a non-mRNA vaccine to its pipeline.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/fda/25/07/46423319/gsk-seeks-fda-nod-to-broaden-rsv-vaccine-for-younger-at-risk-adults" rel="noreferrer noopener">GSK Seeks FDA Nod To Broaden RSV Vaccine For Younger At-Risk Adults</a>
The acquisition also adds &#8216;Molecular Clamp,&#8217; a technology stabilizing viral proteins in their native shape, enabling the immune system to recognize and respond to them more effectively.
The approach enables quicker development of fully liquid combination vaccines stored at standard refrigeration temperatures (2–8°C), eliminating the need for freezing or freeze-drying, thereby simplifying manufacturing and distribution.
Furthermore, fully liquid vaccines can be made available in prefilled syringes, enhancing ease of use, safety, and operational efficiency across healthcare settings.&nbsp;
Under the terms of the agreement, Sanofi would <a target="_blank" href="https://www.sanofi.com/en/media-room/press-releases/2025/2025-07-22-05-30-00-3119150" rel="noreferrer noopener">acquire</a> all of Vicebio&#8217;s share capital for a total upfront payment of $1.15 billion, with potential milestone payments of up to $450 million based on development and regulatory achievements.
The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions, including receipt of regulatory approvals. The acquisition will not have a significant impact on Sanofi&#8217;s financial guidance for 2025.
Vicebio&#8217;s pipeline includes VXB-241, a bivalent vaccine candidate targeting RSV and hMPV, currently in an exploratory phase 1 study in older adults, and VXB-251, a preclinical trivalent vaccine candidate targeting RSV, hMPV, and parainfluenza virus Type 3 (PIV3).
This acquisition reinforces Sanofi&#8217;s commitment to innovation in respiratory vaccines. In June, Sanofi said it is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure broad availability well ahead of the 2025-2026 RSV season, which typically starts in November and <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45839621/beyfortus-output-tripled-as-sanofi-astrazeneca-scale-up-for-rsv-season" rel="noreferrer noopener">runs through March</a>.
Sanofi, in collaboration with its partner AstraZeneca plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), has tripled production capacity and doubled the number of manufacturing sites since the launch of Beyfortus in 2023.
This acquisition follows another significant move by Sanofi in June 2025, when it agreed to acquire Blueprint Medicines Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) for <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45719179/sanofi-expands-rare-immunology-portfolio-with-blueprint-buyout" rel="noreferrer noopener">approximately $9.1 billion</a>.
That acquisition included Ayvakit/Ayvakyt (avapritinib), a rare immunology disease medicine approved in the U.S. and the EU, along with a promising advanced and early-stage immunology pipeline.
Price Action: SNY stock is trading higher by 1.42% to $48.61 at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46551879/ai-bubble-is-more-unhinged-than-dot-com-a-chilling-warning-from-the-inside" target="_blank" rel="noreferrer noopener">AI Bubble Is More Unhinged Than Dot-Com—A Chilling Warning From The Inside</a></li>
</ul>
Photo by HJBC via Shutterstock

BPMC

Sanofi Expands Respiratory Vaccine Portfolio With UK Biotech Buy

UPDATE: AstraZeneca Planning To Invest $50B In The United States Was Announced By The Co. On July 21, 2025

<a href="https://www.nytimes.com/2025/07/22/business/astrazeneca-pharma-tariff-trump.html#:~:text=The%20British%2DSwedish%20drugmaker%20AstraZeneca,percent%20tariff%20on%20imported%20drugs" title="https://www.nytimes.com/2025/07/22/business/astrazeneca-pharma-tariff-trump.html#:~:text=The%20British%2DSwedish%20drugmaker%20AstraZeneca,percent%20tariff%20on%20imported%20drugs">https://www.nytimes.com/2025/07/22/business/astrazeneca-pharma-tariff-trump.html#:~:text=The%20British%2DSwedish%20drugmaker%20AstraZeneca,percent%20tariff%20on%20imported%20drugs</a>.

Politics

'AstraZeneca Joins Pharma Investment Push in U.S. Amid Tariff Threat; The British Drug Maker Plans To Invest $50B In The United States As It Seeks To Appease President Trump' - NY Times

On Monday, AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) released high-level results from the final overall survival (OS) analysis of the FLAURA2 Phase 3 trial of Tagrisso (osimertinib) with the addition of pemetrexed and platinum-based chemotherapy.
The <a target="_blank" href="https://www.astrazeneca.com/media-centre/press-releases/2025/tagrisso-plus-chemotherapy-demonstrated-statistically-significant-and-clinically-meaningful-improvement-in-overall-survival-in-egfr-mutated-advanced-lung-cancer.html" rel="noreferrer noopener">study</a> demonstrated a statistically significant and clinically meaningful improvement in the key secondary endpoint of OS compared to Tagrisso monotherapy for patients with 1st-line locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) <a target="_blank" href="https://www.benzinga.com/general/biotech" rel="noreferrer noopener">non-small cell lung cancer (NSCLC)</a>.​
The final OS analysis demonstrates consistent survival benefit, as reported in the interim OS results.
It builds on the previously presented primary endpoint data, demonstrating the longest-reported median progression-free survival (PFS) in this setting.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/07/46444819/astrazenecas-therapy-for-rare-protein-deposit-condition-fails" rel="noreferrer noopener">AstraZeneca&#8217;s Experimental Therapy Stumbles In Late-Stage Study For Rare Protein Deposit Condition</a>
In September 2023, AstraZeneca released data from the FLAURA2 Phase 3 trial showing Tagrisso (osimertinib) in combination with chemotherapy reduced the risk of disease progression or death by 38% compared to Tagrisso alone in patients with locally advanced (Stage IIIB-IIIC) or metastatic (Stage IV) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC).
According to the investigator&#8217;s assessment, the combination extended median progression-free survival by 8.8 months <a target="_blank" href="https://www.benzinga.com/general/biotech/23/09/34438541/astrazenecas-reinforces-hold-in-lung-cancer-settings-touts-promising-data-from-three-trials?_gl=1&#x2A;8ut96x&#x2A;_gcl_au&#x2A;MTA0Mzg4NjY1MC4xNzUwMDYyNTg3&#x2A;_ga&#x2A;R1MyLjEuczE3NTMwODY0MjgkbzE4OSRnMSR0MTc1MzA5OTgzMSRqNjAkbDAkaDA.&#x2A;_ga_V7ZK73W7N0&#x2A;czE3NTMwODY0MjgkbzE4OSRnMSR0MTc1MzA5OTgzMSRqNjAkbDAkaDA." rel="noreferrer noopener">compared to Tagrisso alone</a>.&nbsp;
In March 2024, results from the FLAURA2 Phase 3 <a target="_blank" href="https://www.astrazeneca.com/media-centre/press-releases/2024/tagrisso-the-addition-chemotherapy-showed-favourable-trend-overall-survival-egfr-mutated-advanced-lung-cancer-further-follow-flaura2-phase-iii-trial.html#!" rel="noreferrer noopener">trial</a> showed Tagrisso, with the addition of chemotherapy,​ provided a clinically meaningful and consistent benefit in subsequent outcomes after disease progression in patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer.
Tagrisso, with the addition of chemotherapy, also demonstrated a favorable trend toward overall survival improvement at two years of follow-up.
With longer follow-up, the safety profile of Tagrisso plus chemotherapy continues to be manageable and consistent with the established profiles of the individual medicines.
Adverse event (AE) rates were higher in the Tagrisso plus chemotherapy arm, driven by well-characterised chemotherapy-related AEs.&nbsp;Discontinuation rates due to AEs and on-target toxicities were low in both arms of the trial.
Based on the FLAURA2 Phase 3 trial, Tagrisso plus chemotherapy is approved in over 80 countries, including the U.S., EU, China, and Japan.
Price Action: AZN stock closed lower by 0.10% at $68.72 on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46514251/taiwan-semiconductor-plans-four-new-fabs-as-ai-gold-rush-continues" target="_blank" rel="noreferrer noopener">Taiwan Semiconductor Plans Four New Fabs As AI Gold Rush Continues</a></li>
</ul>
Photo by Piotr Swat via Shutterstock

AstraZeneca's Multi-Billion Dollar Cancer Drug Tagrisso Improves Overall Survival In Patients With Advanced Lung Cancer

AstraZeneca today announces $50 billion of investment in the United States by 2030, building on America's global leadership in medicines manufacturing and R&amp;D. This investment is expected to create tens of thousands of new, highly skilled direct and indirect jobs across the country powering growth and delivering next generation medicines for patients in America and worldwide.
The cornerstone of this landmark investment is a new multi-billion dollar US manufacturing facility that will produce drug substances for the Company's innovative weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9 and combination small molecule products. The new state-of-the-art center will produce small molecules, peptides and oligonucleotides. This multi-billion dollar capital investment is in addition to the $3.5 billion announced in November 2024.
The drug substance facility, planned to be in the Commonwealth of Virginia, would be AstraZeneca's largest single manufacturing investment in the world. The facility will leverage AI, automation, and data analytics to optimize production.
The $50 billion investment across our R&amp;D and manufacturing footprint in the US over the next five years also includes:
<ul>
<li>Expansion of our R&amp;D facility in Gaithersburg, Maryland</li>
<li>State-of-the-art R&amp;D center in Kendall Square, Cambridge, Massachusetts</li>
<li>Next-generation manufacturing facilities for cell therapy in Rockville, Maryland and Tarzana, California</li>
<li>Continuous manufacturing expansion in Mount Vernon, Indiana</li>
<li>Specialty manufacturing expansion in Coppell, Texas</li>
<li>New sites to supply clinical trials</li>
<li>Our growing research and development investment in novel medicines</li>
</ul>
Collectively, these investments will help deliver AstraZeneca's ambition of reaching $80 billion in Total Revenue by 2030, of which we expect 50% would be generated in the US.
Howard Lutnick, US Secretary of Commerce, said: "For decades Americans have been reliant on foreign supply of key pharmaceutical products. President Trump and our nation's new tariff policies are focused on ending this structural weakness. We are proud that AstraZeneca has made the decision to bring substantial pharmaceutical production to our shores. This historic investment is bringing tens of thousands of jobs to the US and will ensure medicine sold in our country is produced right here."
Governor Glenn Youngkin, Commonwealth of Virginia, said: "I want to thank AstraZeneca for choosing Virginia as the cornerstone for this transformational investment in the United States. This project will set the standard for the latest technological advancements in pharmaceutical manufacturing, creating hundreds of highly skilled jobs and helping further strengthen the nation's domestic supply chain. Advanced manufacturing is at the heart of Virginia's dynamic economy, so I am thrilled that AstraZeneca, one of the world's leading pharmaceutical companies, plans to make their largest global manufacturing investment here in the Commonwealth."
Pascal Soriot, Chief Executive Officer, AstraZeneca, said: "Today's announcement underpins our belief in America's innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally. It will also support our ambition to reach $80 billion in revenue by 2030. I look forward to partnering with Governor Youngkin and his team to work on our largest single manufacturing investment ever. It reflects the Commonwealth of Virginia's desire to create highly skilled jobs in science and technology, and will strengthen the country's domestic supply chain for medicines."

AstraZeneca To Invest $50B In The U.S. By 2030, Building On America's Global Leadership In Medicines Manufacturing And R&D; Investment Will Support AstraZeneca's Ambition To Reach $80B Revenue By 2030, With 50% Generated In The U.S

AstraZeneca's TAGRISSO Plus Chemotherapy Showed Statistically Significant And Clinically Meaningful Improvement In Overall Survival For Patients With 1st-Line Locally Advanced Or Metastatic Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer

Press Releases

DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer

DATROWAY® Approved in the U.S. as First TROP2 Directed Therapy for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

DATROWAY® approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer

Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies

Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial in patients with uncontrolled or treatment resistant hypertension

ENHERTU® Plus Pertuzumab Granted Breakthrough Therapy Designation in the U.S. as First-Line Therapy for Patients with HER2 Positive Metastatic Breast Cancer

TAGRISSO® (osimertinib) plus chemotherapy demonstrated statistically significant and clinically meaningful improvement in overall survival in EGFR-mutated advanced lung cancer

AstraZeneca plans to invest $50 billion in America for medicines manufacturing and R&D

IMFINZI® (durvalumab) granted Priority Review and Breakthrough Therapy Designation in the US for patients with resectable early-stage gastric and gastroesophageal junction cancers

AstraZeneca results: H1 and Q2 2025

CRDF

MBIO

ONCY

TSX:ONC

TYO:4568

VSTM

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Verona Pharma

Viatris

Zoetis

TD Cowen

Argus Research

Goldman Sachs

BMO Capital

Morgan Stanley

Screenshot 2024-09-30 at 9.13.36 PM

TNXP

VRTX

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-09-30 at 5.38.54 PM

Movers & Shakers

COSM

Nestle Sponsored representing Registered Shares Series B

NSRGY

VTRS

How Cosmos Health&#39;s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit

Comments

AstraZeneca

Noticias

Últimas noticias sobre AstraZeneca (NASDAQ:AZN) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL